Business ❯ Investing

Pharmaceuticals

Manufacturing Biotechnology Research and Development Roche AstraZeneca Biopharmaceuticals Eli Lilly Weight Loss Concussion Drugs Merck Vaccine Development Job Creation Biologics Life Sciences Manufacturing Cluster Regeneron Pharmaceuticals Veterinary Medicine Multinational Companies Infrastructure Mexico Ophthalmology Weight-Loss Drugs Contract Manufacturing Global Expansion Mining Drug Manufacturing Biotech Stocks Biologics Manufacturing Healthcare Industry Medical Devices Active Pharmaceutical Ingredients International Collaboration Healthcare Startup Ecosystem International Cooperation International Investment Biomanufacturing Packaging Collaborations

AstraZeneca Buys Stake in Summit to Pursue Cancer Drug Combinations

The equity purchase funds a research pact to test ivonescimab with AstraZeneca’s cancer medicines to speed combination trials.

Eli Lilly Breaks Ground on $6.5 Billion Houston Campus to Make Oral GLP-1 Pill

Bristol Myers Squibb to Build $2.3 Billion Modular Manufacturing Campus in Houston

Lilly and Resilience Announce $750 Million Ohio Expansion for KwikPen and Injectables

Eli Lilly Pours $4.5 Billion Into Indiana Plants, Opens Genetic-Medicine Site

AbbVie to Build $1.4 Billion Injectable-Medicines Campus in Durham, N.C.

UCB Picks Georgia’s Rowen for $2 Billion Biologics Campus

Novo Nordisk Extends Weight‑Loss Lead as Amgen’s Once‑Monthly MariTide Reaches Phase 3

Novo Nordisk Invests €432 Million to Expand Athlone Plant for Oral GLP-1 Tablets

AbbVie to Invest $380 Million in Two North Chicago API Plants

Johnson & Johnson to Build $1 Billion Cell Therapy Plant in Pennsylvania

Eli Lilly Picks Lehigh Valley for $3.5 Billion Plant to Make Next-Gen Weight-Loss Drugs

AstraZeneca Pledges $15 Billion China Expansion Through 2030

Sanofi, Dren Bio Set Autoimmune Collaboration Worth Up to $1.7 Billion With $100 Million Upfront

Merck Breaks Ground on $3 Billion Virginia Plant in $70 Billion U.S. Expansion

AstraZeneca Breaks Ground on $4.5 Billion Virginia Plant With Expanded Cancer and Obesity Drug Production

Eli Lilly Chooses Houston for $6.5 Billion Plant to Produce APIs for Orforglipron and Other Drugs

J&J Commits $2 Billion to 10-Year Fujifilm Deal for North Carolina Biologics Hub

AbbVie to Build $195 Million API Facility in North Chicago

AstraZeneca Commits $50 Billion to U.S. Manufacturing and Research by 2030